Analyses in the primary prevention setting substantiate that LDL-C and Lp(a) are independently associated with CVD risk.
Lipoprotein(a) (Lp(a)) elevation is a causal risk factor for cardiovascular disease. It has however been suggested that elevated Lp(a) causes cardiovascular disease mainly in individuals with high low-density lipoprotein cholesterol (LDL-C) levels. Therefore it was hypothesized that the risk associated with high Lp(a) levels would largely be attenuated at low LDL-C levels.
Results from the Copenhagen City Heart Study prospective population study and the European Prospective Investigation of Cancer-Norfolk prospective population study coordinated by the University of Copenhagen (Prof. Borge Nordestgaard) and Academic Medical Center (Prof. Stroes, dr. Boekholdt) respectively show that lipoprotein(a) and LDL-C are independently associated with cardiovascular disease risk. At LDL-C levels below <2.5 mmol/L, the risk associated with elevated Lp(a) attenuates in a primary prevention setting.
Both beneficiaries in the REPROGRAM project collaborated closely to analyze lipoprotein(a) and LDL-C levels available for 26,102 individuals (16 654 from EPIC-Norfolk and 9448 from the Copenhagen City Heart Study).
The full study article can be found here or doi:10.1093/eurheartj/ehy334